Targeted contrast agents for 1H MRI of tumor microenvironment

Shubhangi Agarwal, Vikram Kodibagkar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In-vivo imaging of cancer can readily provide anatomical and functional information about the tumor, non-invasively, and assist in guiding treatment choices. Proton (1H) magnetic resonance imaging (MRI) is a powerful imaging modality that is particularly useful for studying the dynamic processes in the body with anatomical co-registration. MRI can safely provide diagnostic information to the clinicians repeatedly over the course of therapy. This information on the temporal evolution of tumors can greatly assist the clinicians and researchers in prognosis as well as in selection of better therapeutic protocols and assessment of novel therapies. MRI can be enhanced by the use of contrast agents that enable better delineation of the tumor from its surroundings and these are now routinely used in the clinic for examination of pathologies, particularly cancer. Development of novel contrast agents with specific targeting abilities to the tumor has the potential to greatly improve the diagnosis of the cancer. It can also assist in further improving our understanding of the cancer progression/treatment and aid in designing better therapies. This chapter discusses targeted 1H MRI contrast agents for application in cancer imaging. We begin with an introduction to MRI and the mechanism of MRI contrast agents. We then classify the contrast agents for 1H MRI of tumor microenvironment into two categories, namely lanthanide-based and iron-based, respectively, and discuss the general properties that affect the sensitivity. Targeting agents are also classified based on size and structure (small-molecular, macromolecular, micellar, liposomal and nanoparticulate) and their target in the tumor (vascular versus extravascular). We discuss examples of each category of targeted agent and highlight in vivo applications. Finally we outline the future prospects for this important field of research.

Original languageEnglish (US)
Title of host publicationCancer Therapeutics and Imaging
Subtitle of host publicationMolecular and Cellular Engineering and Nanobiomedicine
PublisherWorld Scientific Publishing Co.
Pages261-316
Number of pages56
ISBN (Electronic)9789813222557
ISBN (Print)9789813222540
DOIs
StatePublished - Jan 1 2017

Fingerprint

Tumor Microenvironment
Magnetic resonance
Contrast Media
Tumors
Magnetic Resonance Imaging
Imaging techniques
Neoplasms
Lanthanoid Series Elements
Oncology
Pathology
Therapeutics
Molecular Structure
Rare earth elements
Blood Vessels
Protons
Iron
Research Personnel

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Engineering(all)
  • Medicine(all)

Cite this

Agarwal, S., & Kodibagkar, V. (2017). Targeted contrast agents for 1H MRI of tumor microenvironment. In Cancer Therapeutics and Imaging: Molecular and Cellular Engineering and Nanobiomedicine (pp. 261-316). World Scientific Publishing Co.. https://doi.org/10.1142/9789813222557_0008

Targeted contrast agents for 1H MRI of tumor microenvironment. / Agarwal, Shubhangi; Kodibagkar, Vikram.

Cancer Therapeutics and Imaging: Molecular and Cellular Engineering and Nanobiomedicine. World Scientific Publishing Co., 2017. p. 261-316.

Research output: Chapter in Book/Report/Conference proceedingChapter

Agarwal, S & Kodibagkar, V 2017, Targeted contrast agents for 1H MRI of tumor microenvironment. in Cancer Therapeutics and Imaging: Molecular and Cellular Engineering and Nanobiomedicine. World Scientific Publishing Co., pp. 261-316. https://doi.org/10.1142/9789813222557_0008
Agarwal S, Kodibagkar V. Targeted contrast agents for 1H MRI of tumor microenvironment. In Cancer Therapeutics and Imaging: Molecular and Cellular Engineering and Nanobiomedicine. World Scientific Publishing Co. 2017. p. 261-316 https://doi.org/10.1142/9789813222557_0008
Agarwal, Shubhangi ; Kodibagkar, Vikram. / Targeted contrast agents for 1H MRI of tumor microenvironment. Cancer Therapeutics and Imaging: Molecular and Cellular Engineering and Nanobiomedicine. World Scientific Publishing Co., 2017. pp. 261-316
@inbook{277d78d5dc0540f68cf9d8d6061bbf39,
title = "Targeted contrast agents for 1H MRI of tumor microenvironment",
abstract = "In-vivo imaging of cancer can readily provide anatomical and functional information about the tumor, non-invasively, and assist in guiding treatment choices. Proton (1H) magnetic resonance imaging (MRI) is a powerful imaging modality that is particularly useful for studying the dynamic processes in the body with anatomical co-registration. MRI can safely provide diagnostic information to the clinicians repeatedly over the course of therapy. This information on the temporal evolution of tumors can greatly assist the clinicians and researchers in prognosis as well as in selection of better therapeutic protocols and assessment of novel therapies. MRI can be enhanced by the use of contrast agents that enable better delineation of the tumor from its surroundings and these are now routinely used in the clinic for examination of pathologies, particularly cancer. Development of novel contrast agents with specific targeting abilities to the tumor has the potential to greatly improve the diagnosis of the cancer. It can also assist in further improving our understanding of the cancer progression/treatment and aid in designing better therapies. This chapter discusses targeted 1H MRI contrast agents for application in cancer imaging. We begin with an introduction to MRI and the mechanism of MRI contrast agents. We then classify the contrast agents for 1H MRI of tumor microenvironment into two categories, namely lanthanide-based and iron-based, respectively, and discuss the general properties that affect the sensitivity. Targeting agents are also classified based on size and structure (small-molecular, macromolecular, micellar, liposomal and nanoparticulate) and their target in the tumor (vascular versus extravascular). We discuss examples of each category of targeted agent and highlight in vivo applications. Finally we outline the future prospects for this important field of research.",
author = "Shubhangi Agarwal and Vikram Kodibagkar",
year = "2017",
month = "1",
day = "1",
doi = "10.1142/9789813222557_0008",
language = "English (US)",
isbn = "9789813222540",
pages = "261--316",
booktitle = "Cancer Therapeutics and Imaging",
publisher = "World Scientific Publishing Co.",

}

TY - CHAP

T1 - Targeted contrast agents for 1H MRI of tumor microenvironment

AU - Agarwal, Shubhangi

AU - Kodibagkar, Vikram

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In-vivo imaging of cancer can readily provide anatomical and functional information about the tumor, non-invasively, and assist in guiding treatment choices. Proton (1H) magnetic resonance imaging (MRI) is a powerful imaging modality that is particularly useful for studying the dynamic processes in the body with anatomical co-registration. MRI can safely provide diagnostic information to the clinicians repeatedly over the course of therapy. This information on the temporal evolution of tumors can greatly assist the clinicians and researchers in prognosis as well as in selection of better therapeutic protocols and assessment of novel therapies. MRI can be enhanced by the use of contrast agents that enable better delineation of the tumor from its surroundings and these are now routinely used in the clinic for examination of pathologies, particularly cancer. Development of novel contrast agents with specific targeting abilities to the tumor has the potential to greatly improve the diagnosis of the cancer. It can also assist in further improving our understanding of the cancer progression/treatment and aid in designing better therapies. This chapter discusses targeted 1H MRI contrast agents for application in cancer imaging. We begin with an introduction to MRI and the mechanism of MRI contrast agents. We then classify the contrast agents for 1H MRI of tumor microenvironment into two categories, namely lanthanide-based and iron-based, respectively, and discuss the general properties that affect the sensitivity. Targeting agents are also classified based on size and structure (small-molecular, macromolecular, micellar, liposomal and nanoparticulate) and their target in the tumor (vascular versus extravascular). We discuss examples of each category of targeted agent and highlight in vivo applications. Finally we outline the future prospects for this important field of research.

AB - In-vivo imaging of cancer can readily provide anatomical and functional information about the tumor, non-invasively, and assist in guiding treatment choices. Proton (1H) magnetic resonance imaging (MRI) is a powerful imaging modality that is particularly useful for studying the dynamic processes in the body with anatomical co-registration. MRI can safely provide diagnostic information to the clinicians repeatedly over the course of therapy. This information on the temporal evolution of tumors can greatly assist the clinicians and researchers in prognosis as well as in selection of better therapeutic protocols and assessment of novel therapies. MRI can be enhanced by the use of contrast agents that enable better delineation of the tumor from its surroundings and these are now routinely used in the clinic for examination of pathologies, particularly cancer. Development of novel contrast agents with specific targeting abilities to the tumor has the potential to greatly improve the diagnosis of the cancer. It can also assist in further improving our understanding of the cancer progression/treatment and aid in designing better therapies. This chapter discusses targeted 1H MRI contrast agents for application in cancer imaging. We begin with an introduction to MRI and the mechanism of MRI contrast agents. We then classify the contrast agents for 1H MRI of tumor microenvironment into two categories, namely lanthanide-based and iron-based, respectively, and discuss the general properties that affect the sensitivity. Targeting agents are also classified based on size and structure (small-molecular, macromolecular, micellar, liposomal and nanoparticulate) and their target in the tumor (vascular versus extravascular). We discuss examples of each category of targeted agent and highlight in vivo applications. Finally we outline the future prospects for this important field of research.

UR - http://www.scopus.com/inward/record.url?scp=85042027781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042027781&partnerID=8YFLogxK

U2 - 10.1142/9789813222557_0008

DO - 10.1142/9789813222557_0008

M3 - Chapter

AN - SCOPUS:85042027781

SN - 9789813222540

SP - 261

EP - 316

BT - Cancer Therapeutics and Imaging

PB - World Scientific Publishing Co.

ER -